Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

IFIrene Fuhrmann

Discussion

Loading...

Member takes

Overview

Analysis uncovers mutation patterns in AML, identifying potential for combination therapies with menin inhibitors.

Key Points

  • Significant findings highlight mutation patterns in AML patients, suggesting potential for targeted therapies.
  • Among 13,458 AML patients analyzed, genetic aberrations were identified, making them candidates for combination therapies.
  • Observational analysis employing RT-PCR and other methods revealed distinct mutation profiles across AML subsets.
  • Frequent co-mutations may enable targeted combination therapies, enhancing treatment efficacy for AML patients.

Cite This Study

Irene Fuhrmann (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e045https://doi.org/10.1182/blood-2025-5248
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review2025 · 7 citations
  2. 2DNMT3A and NPM1 co-mutations in Acute Myeloid Leukemia (AML): A genomic landscape study2025
  3. 3Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia2025
  4. 4The KMT2A-PTD oncoprotein depends on ENL but not menin to drive AML gene expression2025 · 1 citations
  5. 5The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.2025